1	Relative Virulence of SARS-CoV-2 Among Vaccinated and Unvaccinated Individuals
2	Hospitalized with SARS-CoV-2
3	
4	Alicia A. Grima MPH(c), Kiera R. Murison MPH(c), Alison E. Simmons PhD(c) MPH,
5	Ashleigh R. Tuite PhD MPH, David N. Fisman MD MPH
6	
7	
8	
9	Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
10	
11	
12	Address reprint requests and correspondence to:
13	David Fisman, MD MPH FRCP(C)
14	Room 686, 155 College Street, Toronto, Ontario, M5T 3M7
15	Email: <u>david.fisman@utoronto.ca</u>
16	
17	Funding statement: The research was supported by a grant to DNF from the Canadians Institutes
18	for Health Research (2019 COVID-19 rapid researching funding OV4-170360).
19	
20	Declaration of competing interests: Dr. Fisman has served on advisory boards related to
21	influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, Astrazeneca and Sanofi-Pasteur
22	Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the
23	Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario.
24	

25 Abstract

20	
27	Background: The rapid development of safe and effective vaccines against the SARS-CoV-2
28	virus has been a singular scientific achievement. Confounding due to health seeking behaviours
29	and differential testing by vaccination status may bias analyses towards an apparent increase in
30	infection severity following vaccination. We sought to determine whether risks of intensive care
31	unit (ICU) admission and death were diminished significantly by vaccination, even in individuals
32	for whom vaccination failed to prevent hospitalization.
33	Methods: We used data from Ontario, Canada's Case and Contact Management database,
34	merged to a provincial vaccination dataset (COVaxON) to create a time-matched cohort of
35	individuals who were hospitalized with SARS-CoV-2 infection. Each vaccinated individual was
36	matched to up to five unvaccinated individuals based on test date of positive SARS-CoV-2
37	infection. Risk of ICU admission and death were evaluated using multivariable conditional
38	logistic regression. Unmatched exploratory analyses were performed to identify sources of
39	heterogeneity in vaccine effects.
40	Results: In 20,064 individuals (3,353 vaccinated and 16,711 unvaccinated) hospitalized with
41	infection due to SARS-CoV-2 between January 1st, 2021 and January 5th, 2022, vaccination with
42	1, 2, or 3 doses significantly reduced the risk of ICU admission and death. An inverse dose-
43	response relationship was observed between vaccine doses received and both outcomes (adjusted
44	odds ratio (aOR) for ICU admission per additional dose: 0.66, 95% CI 0.62 to 0.71; aOR for
45	death per additional dose: 0.78, 95% CI 0.72 to 0.84). The reduction in risk was greater for ICU
46	admission than for death (P for heterogeneity <0.05), but no significant differences in risk were
47	seen based on infecting variant of concern (VOC).

- 48 Interpretation: We identified a decrease in the risk of ICU admission and death in vaccinated
- 49 individuals compared to unvaccinated, time-matched controls, even when vaccines failed to
- 50 prevent infection sufficiently severe to cause hospitalization. Even with diminished efficacy of
- 51 vaccines against infection with novel VOCs, vaccines remain an important tool for reduction of
- 52 ICU admission and mortality.

54 Introduction

55

The global pandemic of SARS-CoV-2 has sickened hundreds of millions of people, and 56 57 killed millions (1). The rapid development of safe and effective vaccines against the virus has 58 been a singular scientific achievement and has likely prevented many more illnesses and deaths 59 (2-4). However, the ongoing emergence of novel viral variants remains a challenge, with 60 reduced protection against infection seen with the B.1.529 (Omicron) variant that emerged in 61 autumn 2021 (5), though vaccines seem to continue preventing severe illness resulting in 62 hospitalization, intensive care admission, and death. Indeed, the effectiveness of vaccination for 63 prevention of severe outcomes may reflect two different effects, which may be difficult to 64 disentangle: (i) prevention of infection, and (ii) prevention of severe outcomes even when 65 vaccination does not prevent infection. Studies may be further complicated by factors such as 66 decreased propensity to test vaccinated individuals with mild symptoms of respiratory illness, 67 which could produce biases that result in increased apparent severity of infection following vaccination. 68

69 We have previously evaluated the effectiveness of SARS-COV-2 vaccines in the 70 Canadian province of Ontario to prevent infection (6). However, vaccines that result in 71 attenuation of severity, even among individuals in whom they failed to protect against infection, 72 would be of considerable value to vaccinated individuals and to the wider community by limiting 73 consumption of scarce critical care resources. We sought to study the impact of prior 74 vaccination on severity of illness among individuals admitted to hospital with SARS-COV-2 in 75 Ontario, Canada, as a study limited to hospitalized individuals should limit biases introduced by 76 differential testing according to disease severity and vaccination status. As both the propensity 77 to receive vaccination and the dominant viral variant of concern (VOC) has varied over the

- 78 course of the pandemic in Ontario, we used a time-matched cohort to evaluate the adjusted risk
- 79 of intensive care unit (ICU) admission and death in vaccinated and unvaccinated individuals,
- 80 with identically timed infection, admitted to Ontario hospitals. Our primary objective was to
- 81 determine whether the risks of ICU admission and death were diminished significantly by
- 82 vaccination among individuals whose vaccination failed to prevent hospitalization. We also
- 83 performed exploratory analyses to evaluate whether protective effects were modified by
- 84 individuals' characteristics, or by infecting viral variant.
- 85

87 Methods

0	0
0	0
-	-

89 Data Sources

90	We created a time-matched cohort of individuals who were hospitalized due to SARS-
91	CoV-2 infection between January 1st, 2021 and January 5th, 2022. Individuals who had received
92	one, two, or three doses of a SARS-COV-2 vaccine were included as exposed and were matched
93	to unvaccinated individuals based on the test date for SARS-CoV-2. Each vaccinated individual
94	was matched with up to five unvaccinated individuals, acting as controls (7). We identified
95	vaccinated and unvaccinated SARS-CoV-2 cases in the Province's Case and Contact
96	Management (CCM) system, as described elsewhere (8, 9).
97	We included only cases with a unique "pseudo-health card number", permitting linkage
98	with the provincial vaccination COVaxON database (9), which provided information on dose
99	administration, dates, and vaccines used. We considered individuals to be vaccinated 14 days or
100	more after vaccine dose administration (10). We used date of positive testing as a surrogate for
101	onset of infection; when individuals had a test date <14 days from a dose of vaccine, they were
102	considered not to be protected by that dose. For example, an individual tested for infection 2
103	days after their second dose of vaccine would be considered single-dose vaccinated. While
104	information on third vaccine doses was available in COVaxON, third doses were not widely
105	available at the time of the analysis and a small number of hospitalized individuals had received
106	a third dose of vaccine. Consequently, we evaluated individuals based on the number of vaccine
107	doses received, and by classifying them as unvaccinated, single-dose vaccinated, double-dose
108	vaccinated, or triple-dose vaccinated.

109 There have been several waves of the SARS-CoV-2 pandemic in Ontario, with different
110 infecting variants prevalent for each. Initial waves were driven by the Wuhan variant, then waves

111	were driven by Alpha in spring 2021, Delta in summer and autumn 2021 (11), and finally
112	Omicron in December 2021 (12). As such, infecting viral variants in our analysis were classified
113	as non-VOC, N501Y+ variant (including the Alpha, Beta and Gamma variants), or Delta variant,
114	as described elsewhere (9). Individuals were considered infected with the Omicron variant
115	(B.1.1.529) if they had been identified as such through whole genome sequencing, or if they
116	were infected on or after November 10, 2021 with a strain with S-gene target failure or the
117	N501Y mutation. Individuals were also considered infected with the Omicron variant if they had
118	been classed as infected with an unknown VOC after December 13th, 2022. A flow diagram
119	outlining creation of the cohort is presented in Figure 1.
120	
121	Analysis
122	We used our matched cohort to calculate the risk of ICU admission and death among
123	those hospitalized due to SARS-COV-2 using conditional logistic regression models. The models
124	were specified a priori to adjust for age category (treated as a nine-level ordinal variable), sex,
125	healthcare worker status, long-term care residence, comorbidity, and infecting variant. Vaccine
126	status was treated as a four-level nominal variable (zero, one, two, or three doses) where zero
127	doses was used as the referent. Due to the rarity of deaths in healthcare workers, healthcare
128	worker status was not included in models evaluating risk of death.
129	We also performed exploratory restriction analyses in which vaccinated and unvaccinated
130	cases were limited to a single infecting variant (non-VOC, N501Y+ VOC, Delta VOC, or
131	Omicron VOC) to evaluate modification of observed effects of vaccination of ICU admission
132	and death by infecting variant. As conditional logistic regression models failed to converge for
133	some of these models, we modeled the effect of vaccination using unmatched logistic regression

- 134 models, with time trend modeled as a cubic trend function. Lastly, we investigated heterogeneity
- 135 in the adjusted odds ratios (aORs) for ICU admission and death using meta-analytic techniques
- 136 (i.e., graphically using forest plots, and statistically using the meta-analytic Q statistic). The
- 137 study was conducted in accordance with the STROBE guidelines for observational research (13),
- 138 and received ethics approval from the Research Ethics Board at the University of Toronto.

139 Results

140	The final matched cohort consisted of 3,353 vaccinated individuals and 16,711
141	unvaccinated individuals. Most cohort members were aged 50 and over (69.47%) and most were
142	infected with the N501Y+ VOC (33.41%). The cohort was majority male (53.69%), and 21.58%
143	of individuals had a recorded major medical comorbidity. In univariable analyses, vaccinated and
144	unvaccinated individuals differed significantly according to age group, residence in long-term
145	care, comorbidity status, and infecting variant (Table 1). Among vaccinated individuals, 51.12%
146	had received one dose, 44.23% had received two doses, and only 4.65% had received 3 doses.
147	We fit two conditional logistic regression models to assess the risk of being admitted to
148	the ICU and the risk of death in hospitalized individuals (Table 2). Compared to no vaccination,
149	vaccination with a single dose of vaccine (aOR 0.57, 95% CI 0.49 to 0.66), with 2 doses (aOR
150	0.51, 95% CI 0.44 to 0.60), or with 3 doses (aOR 0.56, 95% CI 0.34 to 0.93) significantly
151	reduced ICU admission risk. When vaccination status was treated as a 4-level ordinal variable,
152	we identified a significant inverse dose-response relationship between vaccine doses received
153	and ICU admission risk (aOR per additional dose 0.66, 95% CI 0.62 to 0.71).
154	Vaccination also significantly decreased the risk of death conditional on hospitalization
155	for SARS-COV-2 (aOR for a single vaccine dose 0.5, 95% CI 0.44 to 0.59; aOR for 2 doses
156	0.48, 95% CI 0.40 to 0.56; aOR for 3 doses 0.52, 95% CI 0.31 to 0.86). We identified a
157	significant inverse dose-response relationship between the number of vaccine doses received and
158	risk of death (aOR per additional dose 0.78, 95% CI 0.72 to 0.84).
159	We also performed an exploratory subgroup analysis on the odds of ICU admission and
160	death stratified by the infecting variant. Heterogeneity in the aORs for ICU admission and death
161	is shown in Figure 2. There was no significant heterogeneity between variants within each

- 162 outcome. However, there was significant heterogeneity in vaccine effects based on the outcome
- 163 used, with greater protection against ICU admission than death (p<0.05). Results of stratified
- 164 models are presented in detail in the **Supplementary Tables.**

165 **Discussion**

166 In a cohort of vaccinated and unvaccinated individuals matched on infection timing and 167 hospitalization with SARS-CoV-2 infection in Ontario, Canada, vaccination was associated with 168 a decreased risk of ICU admission and death after adjustment for confounding factors such as 169 age, sex, healthcare worker status, long-term care residence, comorbidity status, and infecting 170 variant. A reduced risk of severe outcomes with increased number of vaccine doses received was 171 also seen. The time-matched nature of our design suggests that our findings are unlikely to be 172 due to changes in vaccine prioritization or dominant circulating variants over time. Restriction 173 to hospitalized individuals makes it less likely that our findings are biased by differential testing 174 in vaccinated and unvaccinated individuals. We postulate that this might result in confounding 175 and selection bias, inasmuch as vaccinated individuals may be less likely to be tested for mild 176 symptoms of infection but may be more likely to be tested overall.

177 The significant protective effects of vaccination against ICU admission and death were 178 seen for both the N501Y+ and Delta variants in exploratory restriction analyses. While we did 179 not identify significant protection against the Omicron variant in restriction analyses, this likely 180 reflects low statistical power due to recent Omicron emergence. We found no evidence for 181 heterogeneity in effect according to infecting variant. We did, however, identify greater 182 protection against ICU admission than against death with vaccines. It is possible that this may 183 relate to the protective effect seen with long-term care residence, adjusted for other covariates, 184 but the increased risk of death associated with this factor.

Protection against infection and symptomatic infection has declined with the emergence of novel variants of concern, most notably the Omicron variant (5, 14-17). While recent data suggest that booster doses of mRNA vaccines substantially restore vaccine efficacy (16, 17), our


188 analysis shows that prior partial vaccination can provide benefits to individuals and health 189 systems even when vaccines fail to prevent infection, or even hospitalization, and remains an 190 important pillar of the public health response to the SARS-CoV-2 pandemic. 191 The effects we demonstrate here are not unique to SARS-CoV-2 and we have previously 192 identified similar effects with prior pneumococcal and influenza vaccination (18, 19). As with 193 that earlier work, an important limitation here is the inability to ensure that the effects we 194 observe are not at least in part due to residual confounding. This is a potential limitation of any 195 cohort study; and is one that will be the focus of future work. The relatively recent emergence of 196 the Omicron variant, and the lags associated with critical illness and death, results in the lack of 197 statistical power to estimate Omicron-specific protections as noted above. Unfortunately, 198 ongoing high rates of SARS-CoV-2 hospitalizations, critical illnesses, and deaths in Ontario 199 mean that we will be able to address this potential limitation in the months ahead. 200 In summary, we identified a decrease in the risk of ICU admission and death in 201 hospitalized, vaccinated individuals compared to hospitalized, unvaccinated individuals, matched 202 for infection timing, in Ontario, Canada. Our analysis further emphasizes the critical importance 203 of high rates of vaccination for protection of community health and reducing the impacts of 204 SARS-CoV-2 on ICU capacity during the pandemic. 205

206 Acknowledgements

The authors with to thank the staff at Public Health Ontario and Ontario's public health units for collecting, sequencing, analyzing, and providing access to the data used for this analysis.

Figure 1: Flow diagram for the creation of the matched cohort.

NOTE: CCM, "case and contact management system" (Ontario's line list database); COVaxON is Ontario's Provincial vaccination database.



	Vaccinated	(%)	Unvaccinated Controls	(%)	Total	(%)	P-value
Ν	3,353		16,711		20,064		
Outcome							
ICU Admission	467	13.93%	3,819	22.85%	4,286	21.36%	< 0.001
Death	517	15.42%	1,849	11.06%	2,366	11.79%	< 0.001
Age Group							
0-9 or 10-19*	32	0.95%	1,038	6.21%	1,070	5.33%	< 0.001
20-29	52	1.55%	905	5.42%	957	4.77%	
30-39	96	2.86%	1,665	9.96%	1,761	8.78%	
40-49	142	4.24%	2,195	13.14%	2,337	11.65%	
50-59	281	8.38%	3,108	18.60%	3,389	16.89%	
60-69	576	17.18%	3,376	20.20%	3,952	19.70%	
70-79	798	23.80%	2,669	15.97%	3,467	17.28%	
80+	1,376	41.04%	1,754	10.50%	3,130	15.60%	
Male	1,838	54.82%	8,935	53.47%	10,773	53.69%	0.135
Healthcare Worker	16	0.48%	88	0.53%	104	0.52%	0.716
Long-Term Care	102	3.04%	93	0.56%	195	0.97%	< 0.001
Comorbidity							
Any Significant Comorbidity	1,088	32.45%	3,242	19.40%	4,330	21.58%	< 0.001
Asthma	79	2.36%	344	2.06%	423	2.11%	0.274
Hematological Disease	47	1.40%	136	0.81%	183	0.91%	0.001
Cardiac Disease	578	17.24%	1,662	9.95%	2,240	11.16%	< 0.001
COPD	142	4.24%	276	1.65%	418	2.08%	0.628
Diabetes	344	10.26%	1,110	6.64%	1,454	7.25%	< 0.001
Renal Disease	138	4.12%	226	1.35%	364	1.81%	< 0.001
Neurological Disease	90	2.68%	186	1.11%	276	1.38%	< 0.001
Obesity	49	1.46%	244	1.46%	293	1.46%	0.996

Table 1: Baseline characteristics of the matched cohort.

Liver Disease	35	1.04%	73	0.44%	108	0.54%	< 0.001
Immune Compromise	215	6.41%	448	2.68%	663	3.30%	< 0.001
Infecting Variant							
VOC Not Detected	69	2.06%	432	2.59%	501	2.50%	< 0.001
N501Y+ VOC	1,056	31.49%	5,648	33.80%	6,704	33.41%	
Delta VOC	954	28.45%	5,362	32.09%	6,316	31.48%	
Presumptive Omicron VOC	645	19.24%	2,917	17.46%	404	2.01%	
Other VOC	49	1.46%	207	1.24%	256	1.28%	
Unknown	580	17.30%	2,145	12.84%	5,883	29.32%	

*Age groups combined due to small cells (≤5). NOTE: COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; VOC, variant of concern.

Covariate	Crude OR	Lower CI	Upper CI	P-value	Adjusted OR*	Lower CI	Upper CI	P-value
		ICU Adm	ission					
Vaccinations Received								
Unvaccinated (Referent)	1.00				1.00			
1 Dose	0.57	0.49	0.66	< 0.001	0.51	0.44	0.59	< 0.001
2 Doses	0.51	0.44	0.60	< 0.001	0.48	0.40	0.56	< 0.001
3 Doses	0.56	0.34	0.93	0.024	0.52	0.31	0.86	0.011
Age Group (Per 10-year Increase)	1.03	1.01	1.05	0.001	1.07	1.05	1.09	< 0.001
Male	1.42	1.32	1.53	< 0.001	1.43	1.33	1.55	< 0.001
Healthcare Worker	0.67	0.38	1.18	0.164	0.76	0.43	1.35	0.348
Long-Term Care	0.39	0.23	0.69	0.001	0.43	0.25	0.75	0.003
Any Significant Comorbidity	1.08	0.98	1.18	0.104	1.12	1.02	1.22	0.019
Infecting Variant								
Non-VOC, Unknown, Other VOC (Referent)	1.00				1.00			
N501Y+ VOC	1.01	0.89	1.15	0.831	1.16	1.01	1.33	0.040
Delta VOC	1.80	1.61	2.01	< 0.001	1.78	1.56	2.04	< 0.001
Presumptive Omicron VOC	0.50	0.39	0.65	< 0.001	1.04	0.77	1.39	0.816
		Deat	h					
Vaccinations Received								
Unvaccinated (Referent)	1.00				1.00			
1 Dose	1.52	1.32	1.75	< 0.001	0.68	0.58	0.80	< 0.001
2 Doses	1.38	1.17	1.63	< 0.001	0.62	0.51	0.74	< 0.001
3 Doses	1.98	1.05	3.73	0.034	0.83	0.42	1.61	0.575
Age Group (Per 10-year Increase)	1.69	1.63	1.75	< 0.001	1.77	1.70	1.84	< 0.001
Male	1.55	1.41	1.71	< 0.001	1.75	1.58	1.95	< 0.001

Table 2: Odds ratios and 95% confidence intervals from conditional logistic regression on intensive care unit admission and death due to SARS-COV-2.

Long-Term Care	3.39	2.22	5.17	< 0.001	1.67	1.05	2.66	0.029
Any Significant Comorbidity	1.66	1.50	1.85	< 0.001	1.40	1.25	1.57	< 0.001
Infecting Variant								
Non-VOC, Unknown, Other VOC (Referent)	1.00				1.00			
N501Y+ VOC	1.09	0.93	1.27	0.301	1.06	0.89	1.27	0.517
Delta VOC	1.33	1.15	1.54	< 0.001	1.47	1.22	1.77	< 0.001
Presumptive Omicron VOC	1.31	0.89	1.93	0.172	2.71	1.69	4.33	< 0.001

*ICU admission adjusted for age group, sex, healthcare worker, long-term care, comorbidity, and infecting variant; Death adjusted for age group, sex, long-term care, comorbidity, and infecting variant. NOTE: CI, confidence Interval; OR, odds ratio; VOC, variant of concern.

Figure 2: Forest plot to evaluate heterogeneity between estimates by infecting variant and outcome.

The analysis is stratified by outcome, with results for death in the upper rows, and ICU admission below. **NOTE:** CI, confidence interval; ICU, intensive care unit; I-V, contribution of within-stratum variance to overall variance; n501, N501Y-positive variant; VOC, variant of concern.

outcome and VOC	Dose		Odds ratio (95% CI)	% Weight
Death				
501	1		0.62 (0.51, 0.76)	17.91
501	2		1.14 (0.60, 2.17)	1.79
Delta	1	-	0.57 (0.40, 0.81)	6.01
Delta	2		0.61 (0.48, 0.77)	13.69
Delta	3		0.80 (0.35, 1.81)	1.11
Omicron	1		- 1.00 (0.22, 4.60)	0.32
Omicron	2		0.47 (0.28, 0.78)	2.89
Omicron	3		0.70 (0.27, 1.80)	0.83
on-VOC	1	<u> </u>	0.99 (0.46, 2.11)	1.30
Ion-VOC	2	• + +	0.29 (0.06, 1.46)	0.28
Subgroup, IV	(I ² = 0.0%, p = 0.541)	♦	0.63 (0.55, 0.71)	46.14
CU Admissio	n			
501	1	+	0.54 (0.44, 0.66)	18.44
501	2		0.73 (0.35, 1.53)	1.36
Delta	1	-	0.55 (0.40, 0.75)	7.72
Delta	2	-	0.44 (0.35, 0.55)	14.91
Delta	3 -	• •	0.38 (0.16, 0.92)	0.95
Omicron	1		0.63 (0.21, 1.85)	0.64
Omicron	2		0.38 (0.27, 0.53)	6.71
Omicron	3		0.60 (0.33, 1.10)	2.02
Ion-VOC	1		0.74 (0.30, 1.80)	0.94
Ion-VOC	2	• + + -	0.24 (0.03, 1.92)	0.17
Subgroup, IV	(l ² = 0.0%, p = 0.545)	0	0.49 (0.44, 0.56)	53.86
Overall, IV (I ²	= 17.5%, p = 0.236) between groups: p = 0	\$	0.55 (0.51, 0.60)	100.00

Supplementary Tables

Table S1: Adjusted odds ratios and 95% confidence intervals from logistic regression on intensive care unit admission due to SARS-COV-2, stratified by infecting SARS-COV-2 variant.

Covariate	Adjusted OR	Lower CI	Upper CI	P-value
	<i>N501Y</i> +*			
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.54	0.44	0.66	< 0.001
2 Doses	0.73	0.34	1.53	0.400
3 Doses	-	-	-	-
	Delta*			
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.55	0.41	0.75	< 0.001
2 Doses	0.44	0.35	0.55	< 0.001
3 Doses	0.38	0.16	0.92	0.032
	Omicron**			
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.63	0.22	1.85	0.403
2 Doses	0.38	0.28	0.53	< 0.001
3 Doses	0.60	0.33	1.10	0.096

*Adjusted for age group, sex, healthcare worker, long-term care, comorbidity, and time cubed.

**Adjusted for age group, sex, long-term care, comorbidity, and time cubed.

NOTE: CI, confidence interval; OR, odds ratio; VOC, variant of concern.

Covariate	Adjusted OR*	Lower CI	Upper CI	P-value
	<i>N501Y</i> +			
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.62	0.51	0.76	< 0.001
2 Doses	1.14	0.60	2.17	0.682
3 Doses	-	-	-	-
Delta				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.57	0.40	0.81	0.002
2 Doses	0.61	0.48	0.77	< 0.001
3 Doses	0.80	0.35	1.81	0.592
Omicron				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	1.00	0.22	4.60	0.996
2 Doses	0.47	0.29	0.78	0.003
3 Doses	0.70	0.27	1.80	0.456

Table S2: Adjusted odds ratios and 95% confidence intervals from logistic regression on death due to SARS-COV-2, stratified by infecting SARS-COV-2 variant.

*Adjusted for age group, sex, long-term care, comorbidity, and time cubed.

NOTE: CI, confidence interval; OR, odds ratio; VOC, variant of concern.

References

 Johns Hopkins University Coronavirus Resource Centre. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU).
 Available via the Internet at <u>https://coronavirus.jhu.edu/map.html</u>. Last accessed December 27, 2021.

. 2021.

2. Kreier F. 'Unprecedented achievement': who received the first billion COVID vaccinations? Nature. 2021.

3. Mesle MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47).

4. Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Aff (Millwood). 2021;40(9):1465-72.

5. Hogan AB, Wu SL, Doohan P, Watson OJ, Winskill P, Charles G, et al. Report 48 - The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant. Available via the Internet at <u>http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-48-global-omicron/</u>. Last accessed December 17, 2021. 2021.

6. Fisman DN, Lee N, Tuite AR. Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2. medRxiv. 2022.

7. Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-tocase ratio in matched case-control studies. Am J Epidemiol. 1999;149(2):195-7.

8. Fisman DN, Greer AL, Hillmer M, O'Brien SF, Drews SJ, Tuite AR. COVID-19 case age distribution: correction for differential testing by age. medRxiv. 2020:2020.09.15.20193862.

9. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021;193(42):E1619-E25.

10. Ontario Ministry of Health. COVID-19 Fully Vaccinated Status in Ontario. Available via the Internet at

https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19 fully vaccinated status ontario.pdf. Last accessed December 2, 2021. 2021.

11. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2

Variants in Ontario, Canada. medRxiv. 2021:2021.07.05.21260050.

 Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv. 2021:2021.12.14.21267755.

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
statement: guidelines for reporting observational studies. Bull World Health Organ.
2007;85(11):867-72.

14. Khoury DS, Steain M, Triccas JA, Sigal A, Davenport MP, Cromer D. A meta-analysis of Early Results to predict Vaccine efficacy against Omicron. medRxiv.

2021:2021.12.13.21267748.

15. Rufino J, Baquero C, Frey D, Glorioso CA, Ortega A, Reščič N, et al. Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection. medRxiv. 2022:2022.01.21.22269636.

16. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv. 2022:2021.12.30.21268565.

Kislaya I, PERALTA SANTOS A, Borges V, Vieira L, Sousa C, Ferreira B, et al.
 Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing
 SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants.
 medRxiv. 2022:2022.01.31.22270200.

18. Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med. 2007;167(1):53-9.

19. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006;42(8):1093-101.